Clinical Trial Update: Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenvatinib for recurrent hepatocellular carcinoma after liver transplantation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Emory University | Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Status: TERMINATED